Format

Send to

Choose Destination
Blood. 2019 Jun 26. pii: blood.2019000854. doi: 10.1182/blood.2019000854. [Epub ahead of print]

Prevalence of BTK and PLCG2 mutations in a real‑life CLL cohort still on ibrutinib after three years: a FILO group study.

Author information

1
Hematology, Hopital Robert Debré, CHU Reims, France aquinquenel@chu-reims.fr.
2
Hôpitaux Universitaires de Strasbourg, France.
3
Hopital Avicenne, Assistance Publique-Hopitaux de Paris, France.
4
Hematology, Institut Universitaire du Cancer de Toulouse-Oncopole, France.
5
Hôpital Avicenne (APHP), France.
6
Service d'Hématologie Biologique, Hôpital Avicenne, Assistance Publique - Hôpitaux de Paris, France.
7
hematology, Hopital Haut Leveque, France.
8
CHRU Bretonneau, France.
9
CHU Clermont-Ferrand, France.
10
Nancy University Hospital, France.
11
Pitié-Salpêtrière, France.
12
cochin, France.
13
Hematologie, Centre Léon Bérard, France.
14
Hematology, Hôpital Robert Debré, France.
15
INSERM UMR-S1147, CNRS SNC5014; Paris Descartes University,, France.
16
URC-CRC, Hôpital Avicenne, APHP, France.
17
Hematologie Biologique, Hopital Avicenne, APHP, France.
18
Hematology, Aphp, France.

Abstract

Mutational analyses performed following acquired ibrutinib resistance have suggested that chronic lymphocytic leukemia (CLL) progression on ibrutinib is linked to mutations in the Bruton's tyrosine kinase (BTK) and/or phospholipase Cg2 (PLCG2) genes. However, mutational information for patients still on ibrutinib is limited. Here, we report a study aimed to provide a 'snapshot' of the prevalence of mutations in a real-life CLL cohort still on ibrutinib after at least three years of treatment. Of 204 patients who initiated ibrutinib via an early access program at 29 French Innovative Leukemia Organization (FILO) centers, 63 (31%) were still on ibrutinib after three years and 57 provided a fresh blood sample. Thirty patients had a CLL clone {greater than or equal to}0.5 G/L, enabling next‑generation sequencing (NGS); BTK and PLCG2 mutations were detected in 57% and 13% of the NGS samples, respectively. The presence of a BTKmutation was significantly associated with subsequent CLL progression, at a median 8.5 months from sample collection (P=0.0005 versus noBTKmutation). Our findings support that mutational analysis should be considered in patients receiving ibrutinib who have residual clonal lymphocytosis, and that clinical trials are needed to evaluate whether patients with a BTK mutation may benefit from an early switch to another treatment.

PMID:
31243043
DOI:
10.1182/blood.2019000854

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center